Experience

Davis Polk advised the underwriters on the SEC-registered initial public offering by Progyny, Inc. of 11,500,000 common shares, consisting of 6,700,000 shares sold by Progyny and 4,800,000…

Davis Polk advised the underwriters in connection with an initial public offering of 8,047,227 American Depositary Shares of Innate Pharma S.A. and a concurrent private placement of 4,452…

Davis Polk advised the underwriters in connection with the $150 million initial public offering of 10,000,000 American Depositary Shares of BioNTech SE. In addition, the underwriters have…

Davis Polk advised the underwriters in connection with the $97.75 million initial public offering of 6,516,667 shares of common stock of Aprea Therapeutics, Inc., which includes 850,000…

Davis Polk advised TPG Capital, the private equity platform of global alternative asset firm TPG, on its acquisition of Convey Health Solutions from New Mountain Capital and related…

Davis Polk is advising the Goldman Sachs Merchant Banking Division in connection with its investment in MedVet. Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment…

Davis Polk advised the representatives of the several underwriters in connection with the $125 million initial public offering of common stock by Atreca, Inc. The common stock is listed on…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $155 million initial public offering by Personalis, Inc. The common stock is listed…

Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc.,…

Davis Polk advised the underwriters in connection with an initial public offering of 5,750,000 shares of common stock of IDEAYA Biosciences, Inc. at $10.00 per share (which includes the…